Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to compare maintenance therapy with pemetrexed plus best supportive care (BSC) versus placebo plus BSC, in terms of objective progression-free survival (PFS) time in patients with Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or IV non squamous NSCLC whose disease has not progressed during 4 cycles of pemetrexed + cisplatin induction chemotherapy.
Critère d'inclusion
- Advanced Non-Squamous Non Small Cell Lung cancer